{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Overall survival of participants who receive neoadjuvant nivolumab combined with ipilimumab, defined as time from enrollment on study to death from any cause.","groups":[{"description":"Individuals in this group will receive a combination of two immunotherapy drugs (nivolumab and ipilimumab) before and after surgery to remove their cancer.\n\nNivolumab: Nivolumab is an immunotherapy drug (a type of drug that helps the immune system fight cancer) that is often used with ipilimumab as the first treatment in adults with mesothelioma whose disease cannot be removed by surgery. The drug will be given as an IV infusion.\n\nIpilimumab: Ipilimumab is a type of immunotherapy drug known as a checkpoint inhibitor, which helps the immune system attack cancer cells.","id":"OG000","title":"All Participants in Study Who Have Mesothelioma"}],"populationDescription":"Data not collected.","reportingStatus":"POSTED","timeFrame":"42 Months","title":"Overall Survival of Participants Who Take Nivolumab Combined With Ipilimumab Before Surgery","type":"SECONDARY"}